About the Anti-Coagulant Drugs Market
Anticoagulants have been used for over 80 years to treat clotting disorders. It is used as a first line of defense for disorders such as deep vein thrombosis (DVT), pulmonary embolism, AF, and acute coronary syndrome. With the advent of time, traditional therapies are replaced by novel oral anticoagulants, which have better safety and efficacy profiles.

The 1990s saw rapid development in the field of direct thrombin inhibitors. Though these drugs, such as hirudin, have been in use from the early 19th century, they were accepted with the development of genetic engineering technology. The recombinant forms, such as desirudin, are also available in the market. During the same period, the focus shifted toward the development of factor Xa inhibitors, and by early 2000s, the first indirect factor Xa inhibitor, fondaparinux, was released into the market. These drugs were administered by parenteral route.

Technavio’s analysts forecast the anti-coagulants market in the US to grow at a CAGR of 6.67% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the anti-coagulants market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.

Technavio's report, Anti-Coagulants Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Johnson & Johnson
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Sanofi
• Daiichi Sankyo

Other prominent vendors
• Armatheon Inc.
• Aspen
• AstraZeneca
• Bayer
• Cellceutix
• Cosmo Pharmaceuticals SA
• CSL Behring, Eisai, GSK
• Marathon Pharmaceuticals LLC
• Ockham Biotech
• Perosphere
• Portola Pharmaceuticals
• Sagent Pharmaceuticals Inc.
• The Medicines Company
• Urigen Pharmaceuticals Inc.
• Valeant Pharmaceuticals

Market driver
• Growing prevalence of coagulation disorders
• For a full, detailed list, view our report

Market challenge
• Side-effects associated with drugs
• For a full, detailed list, view our report

Market trend
• Expected exploitation of new therapeutic use
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.